Pfizer (NYSE:PFE) Posts Better-Than-Expected Sales In Q4
Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results , with sales up 21.9% year on year to $17.76 billion. On the other hand, the company’s full-year revenue guidance of $62.5 billion at the midpoint came in 0.
Pfizer Q4 Earnings Preview: Strong top line growth expected on COVID-19 product demand
Pfizer (PFE) is set to announce Q4 earnings, with analysts expecting a $0.46 profit per share and $17.26B revenue.
Pfizer stock rises after beating Q4 expectations
Pfizer (NYSE: PFE) posted adjusted earnings per share of $0.63 for Q4, exceeding the analyst consensus of $0.48. Revenue came in at $17.8 billion, above expectations of $17.28 billion.
Pfizer Shares Rise on Better-Than-Expected 4Q
The positive quarter caps a busy year of cost cutting and pressure from an activist investor as Pfizer has sought to turn around company performance. Shares rose 1.2% to $26.51 soon after market open.
Pfizer tops earnings estimates as Covid product sales beat expectations and cost cuts pay off
The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its Covid business and stock price.
Pfizer's Q4 Earnings Beat Estimates, Non-Covid Drugs Drive Sales
Pfizer PFE reported fourth-quarter 2024 adjusted earnings per share of 63 cents, which beat the Zacks Consensus Estimate of 48 cents per share. The company had recorded earnings of 10 cents per share in the year-ago quarter.
Goldman Sachs cuts Pfizer stock price target to $32 from $33
The anticipation surrounding dose optimization data for Pfizer (NYSE:PFE)'s obesity treatment, danuglipron, was also mentioned as a point of interest for the first quarter. However, the analyst ...
Pfizer Rises on Q4 Earnings Beat, 2025 Outlook Reaffirmed
Pfizer beats Q4 estimates with 24.9% revenue growth, reaffirming 2025 guidance and targeting $4.5 billion in cost savings ...
Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down
Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...
The Armenian Reporter18h
Welch Group LLC Reduces Stock Holdings in Pfizer Inc. (NYSE:PFE)
Welch Group LLC cut its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 35.1% in the fourth quarter, HoldingsChannel reports ...
Here’s Why Pfizer Inc. (PFE) Is Among the Best Dividend Stocks Under $30
Dividend stocks have remained a focal point for investors, especially amid market volatility and the growing need for steady ...
Pfizer Q4 Results Beat Market; Confirms FY25 Outlook - Update
Drug major Pfizer Inc. (PFE), while reporting a profit in its fourth quarter, compared to prior year's loss, on Tuesday reaffirmed ...
The Pharma Letter21h
Pfizer beats sales and earnings forecast in 4th-qtr
US pharma giant Pfizer reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial ...
Pfizer (NYSE:PFE) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows ...
Pfizer (NYSE:PFE) Price Target Cut to $29.00 by Analysts at Citigroup
Pfizer (NYSE:PFE – Get Free Report) had its price objective decreased by equities research analysts at Citigroup from $30.00 ...
Hosted on MSN4h
Amgen, Merck and Pfizer Release Latest Quarterly Earnings, Share 2025 Plans
Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...